Transgene SA, a developer of oncolytic virus therapies and an indirect subsidiary of the Institut Mérieux Group, has raised €65.5 million in a two-part share offering enabling it to carry forward an ambitious clinical trial programme for its portfolio of immunotherapies.
4SC AG, a small molecule developer with a service operation, reported increased revenues and a smaller loss for 2013 as a result of austerity measures. But its holding of cash and marketable securities at year-end declined sharply.
GlaxoSmithKline Plc has withdrawn its marketing authorisation application in Europe for the combination melanoma treatment trametinib/dabrafenib.
Nanobiotix SA, which produces nanoparticles designed to increase the efficacy of radiotherapy, has increased its capital with a €28.1 million offering on the NYSE Euronext Paris exchange. Proceeds will be used to advance its lead cancer agent – a medical device.
A new medicine and two imaging agents have been recommended for marketing in Europe under the European Union’s conditional licensing procedure – a procedure that enables medicines to reach patients on the basis of a limited data package.
Horizon Discovery Group Plc has raised £68.6 million with an initial public offering on the London Stock Exchange’s Alternative Investment Market, well in excess of the originally targeted £25 million. Horizon will use the funds to expand the sales of its genomics research tools.
Evotec AG has announced the acquisition of a small asset management company, Bionamics GmbH, to help it accelerate the translation of academic innovations into assets for the biotech and pharmaceutical industry. Financial terms weren’t disclosed.
Zealand Pharma A/S had revenue of DKK 6.6 million (€0.9 million) for 2013, wholly made up of royalty payments on sales of its first marketed product, Lyxumia (lixisenatide), for Type 2 diabetes. Revenue in 2012 was DKK 223.6 million and milestone based.
The European Medicines Agency is inviting pharmaceutical companies to participate in a pilot project under which it will evaluate ‘adaptive licensing’ as a way of getting new medicines to patients earlier, under certain controlled situations.
A Phase 3 trial of a MAGE-A3 cancer vaccine has failed to significantly extend disease-free survival in patients with non-small lung cancer – the first and second co-primary endpoints, according to the developer GlaxoSmithKline Plc.